

Pal Miheller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5934959/publications.pdf>

Version: 2024-02-01

57
papers

1,850
citations

218381

26
h-index

264894

42
g-index

73
all docs

73
docs citations

73
times ranked

2897
citing authors

#	ARTICLE	IF	CITATIONS
1	New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort. <i>American Journal of Gastroenterology</i> , 2008, 103, 665-681.	0.2	135
2	Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1656-1662.	0.9	115
3	Inflammation, Adenoma and Cancer: Objective Classification of Colon Biopsy Specimens with Gene Expression Signature. <i>Disease Markers</i> , 2008, 25, 1-16.	0.6	92
4	Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA. <i>PLoS ONE</i> , 2014, 9, e115415.	1.1	87
5	The Impact of Matrix Metalloproteinases and Their Tissue Inhibitors in Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2012, 30, 289-295.	0.8	77
6	Colorectal Cancer in Patients with Inflammatory Bowel Disease: The True Impact of the Risk. <i>Digestive Diseases</i> , 2015, 33, 52-57.	0.8	70
7	Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 984-992.	0.9	69
8	Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: A case-control study. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 1302-1306.	0.6	68
9	Effect of Proton-Pump Inhibitor Therapy on Serum Chromogranin A Level. <i>Digestion</i> , 2011, 84, 22-28.	1.2	68
10	Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1379-1384.	0.9	58
11	Pancreatic Autoantibodies Are Associated with Reactivity to Microbial Antibodies, Penetrating Disease Behavior, Perianal Disease, and Extraintestinal Manifestations, But Not with NOD2/CARD15 or TLR4 Genotype in a Hungarian IBD Cohort. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 365-374.	0.9	58
12	Carcinogenesis in Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2007, 25, 267-269.	0.8	55
13	The Behavior of Matrix Metalloproteinase-9 in Lymphocytic Colitis, Collagenous Colitis and Ulcerative Colitis. <i>Pathology and Oncology Research</i> , 2012, 18, 85-91.	0.9	53
14	Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1394-1398.	0.6	51
15	Prevalence of inflammatory bowel disease among coeliac disease patients in a Hungarian coeliac centre. <i>BMC Gastroenterology</i> , 2015, 15, 141.	0.8	46
16	Have Biologics Changed the Natural History of Crohn's Disease?. <i>Digestive Diseases</i> , 2014, 32, 351-359.	0.8	44
17	Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1908-1915.	0.9	43
18	Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas. <i>PLoS ONE</i> , 2015, 10, e0133836.	1.1	42

#	ARTICLE	IF	CITATIONS
19	Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 283-290.	0.6	39
20	Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 26-30.	0.6	38
21	Matrix Metalloproteinase-9 Expression in the Normal Mucosaâ€“Adenomaâ€“Dysplasiaâ€“Adenocarcinoma Sequence of the Colon. <i>Pathology and Oncology Research</i> , 2008, 14, 31-37.	0.9	36
22	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1063-1075.	3.7	35
23	Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study. <i>BMC Gastroenterology</i> , 2009, 9, 66.	0.8	33
24	Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw203.	0.6	33
25	Infliximab Therapy Improves the Bone Metabolism in Fistulizing Crohnâ€™s Disease. <i>Digestive Diseases</i> , 2006, 24, 201-206.	0.8	26
26	Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 179-192.	1.4	26
27	Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 885-890.	1.0	26
28	Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. <i>British Journal of Nutrition</i> , 2007, 98, 345-350.	1.2	25
29	Chemoprevention of colorectal cancer: feasibility in everyday practice?. <i>European Journal of Cancer Prevention</i> , 2008, 17, 502-514.	0.6	22
30	Malnutrition risk questionnaire combined with body composition measurement in malnutrition screening in inflammatory bowel disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 109, 26-32.	0.1	22
31	Recommendations for identifying Crohnâ€™s disease patients with poor prognosis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 65-76.	1.3	20
32	Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1298-1303.	0.6	17
33	NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 5233.	1.4	17
34	Clinical relevance of changes in bone metabolism in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2010, 16, 5536.	1.4	17
35	The 3â€™UTR NFKBIA Variant Is Associated with Extensive Colitis in Hungarian IBD Patients. <i>Digestive Diseases and Sciences</i> , 2009, 54, 351-359.	1.1	15
36	Celiac disease in a 15-year period of observation (1997 and 2011) in a Hungarian referral centre. <i>European Journal of Internal Medicine</i> , 2013, 24, 461-467.	1.0	13

#	ARTICLE	IF	CITATIONS
37	IGR2096a_1 T and IGR2198a_1 C alleles on IBD5 locus of chromosome 5q31 region confer risk for Crohn's disease in Hungarian patients. <i>International Journal of Colorectal Disease</i> , 2009, 24, 503-507.	1.0	11
38	Low bone mass in microscopic colitis. <i>BMC Gastroenterology</i> , 2011, 11, 58.	0.8	10
39	Automated virtual microscopy of gastric biopsies. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 423-431.	0.7	9
40	Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease. <i>Journal of Emergency Medicine</i> , 2007, 32, 209-210.	0.3	9
41	Thiopurines in Crohn's disease, is there something new?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1505-1514.	1.5	8
42	Does dermatitis herpetiformis result in bone loss as coeliac disease does?: a cross sectional study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 187-193.	0.1	8
43	Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	8
44	Probiotics in the Management of Crohn's disease and Ulcerative Colitis. <i>Current Pharmaceutical Design</i> , 2014, 20, 4556-4560.	0.9	8
45	Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1181-1187.	1.4	7
46	Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologics – Prospective observational cohort study. <i>Dermatologic Therapy</i> , 2022, 35, e15408.	0.8	7
47	Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 174-181.	0.6	6
48	Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 205-213.	1.4	6
49	Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters' Levels, but Has No Effect on Body Composition Parameters. <i>Life</i> , 2021, 11, 535.	1.1	6
50	Nutritional Influences in Selected Gastrointestinal Diseases. <i>Digestive Diseases</i> , 2011, 29, 154-165.	0.8	4
51	Manipulating bone disease in inflammatory bowel disease patients. <i>Annals of Gastroenterology</i> , 2013, 26, 296-303.	0.4	4
52	Methotrexate: Should We Start Using it in Clinical Practice?. <i>Current Drug Targets</i> , 2013, 14, 1480-1489.	1.0	3
53	Letter: suicide risk among adult inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1213-1214.	1.9	2
54	Bone Homeostasis in Intestinal Disorders. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2010, 8, 140-148.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Endoscopic solutions for stricturing Crohn's disease. <i>Interventional Medicine & Applied Science</i> , 2012, 4, 74-77.	0.2	0
56	Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice?. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 871-882.	1.3	0
57	Corrigendum to "Optimising monitoring in the management of Crohn's disease: A physician perspective" [Journal of Crohn's and Colitis volume 7 (2013) 653-669]. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 441.	0.6	0